Published in Blood on October 24, 2002
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res (2009) 1.51
High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res (2010) 1.48
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol (2008) 1.24
Chemoimmunotherapy. Cancer J (2010) 1.13
Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res (2009) 1.11
Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11
Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother (2009) 1.08
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol (2008) 1.03
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med (2013) 0.93
Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine (2008) 0.92
Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci (2008) 0.90
Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol (2009) 0.89
Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. Cancer Gene Ther (2007) 0.87
Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood (2008) 0.87
Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. J Immunol (2009) 0.82
Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther (2009) 0.81
Is there really a specific graft-versus-leukaemia effect? Bone Marrow Transplant (2016) 0.75
Visualization of immune response kinetics in full allogeneic chimeras. Am J Blood Res (2011) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 3.57
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood (2012) 2.72
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood (2009) 2.25
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A (2008) 2.20
Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 2.20
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2008) 2.15
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol (2007) 1.92
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood (2010) 1.89
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A (2011) 1.89
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant (2003) 1.81
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med (2013) 1.69
Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res (2004) 1.67
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 1.65
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol (2012) 1.63
Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity (2012) 1.61
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol (2005) 1.56
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res (2003) 1.56
Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res (2012) 1.53
Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis (2010) 1.53
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res (2009) 1.51
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma (2011) 1.49
Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res (2009) 1.49
Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun (2003) 1.49
High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res (2010) 1.48
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res (2013) 1.47
IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 1.45
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res (2008) 1.43
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant (2009) 1.41
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res (2005) 1.35
LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (2009) 1.33
High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol (2010) 1.33
Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands. Immunol Rev (2006) 1.33
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med (2004) 1.32
B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun (2007) 1.29
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A (2007) 1.28
Cellular vaccine approaches. Cancer J (2010) 1.27
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res (2006) 1.25
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol (2003) 1.25
Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin. Nature (2007) 1.21